Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
13,800
Employees13,800
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
13,800
Employees13,800

ZTS Key Statistics

Market cap
54.68B
Market cap54.68B
Price-Earnings ratio
20.60
Price-Earnings ratio20.60
Dividend yield
1.64%
Dividend yield1.64%
Average volume
6.97M
Average volume6.97M
High today
$125.53
High today$125.53
Low today
$122.01
Low today$122.01
Open price
$122.01
Open price$122.01
Volume
4.78M
Volume4.78M
52 Week high
$177.40
52 Week high$177.40
52 Week low
$115.25
52 Week low$115.25

Stock Snapshot

The current Zoetis(ZTS) stock price is $124.09, with a market capitalization of 54.68B. The stock trades at a price-to-earnings (P/E) ratio of 20.60 and offers a dividend yield of 1.6%.

As of 2025-12-18, Zoetis(ZTS) stock has fluctuated between $122.01 and $125.53. The current price stands at $124.09, placing the stock +1.7% above today's low and -1.2% off the high.

Zoetis(ZTS) shares are trading with a volume of 4.78M, against a daily average of 6.97M.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $177.40 and a 52-week low of $115.25.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $177.40 and a 52-week low of $115.25.

ZTS News

TipRanks 8h
Zoetis price target lowered to $160 from $175 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $160 from $175 and keeps an Overweight rating on the shares. For healthcare technology and pro...

Simply Wall St 20h
Assessing Zoetis Valuation After a 25% Share Price Slide and Cash Flow Forecasts

For investors wondering if Zoetis is starting to look like a bargain after a rough stretch, this is the kind of setup where a deeper valuation check can help un...

Assessing Zoetis Valuation After a 25% Share Price Slide and Cash Flow Forecasts
Nasdaq 23h
These 2 Healthcare Stocks Just Declared Dividend Raises

Key Points One is a sector mainstay that has now raised its payout 17 years in a row. The other is a big player in the animal healthcare space. It's not too...

These 2 Healthcare Stocks Just Declared Dividend Raises

Analyst ratings

68%

of 22 ratings
Buy
68.2%
Hold
31.8%
Sell
0%

More ZTS News

TipRanks 3d
Zoetis Stock Climbs as $1.75B Convertible Plan Boosts Confidence in Growth Strategy

Zoetis (ZTS) stock rose over 2% on Monday after the animal health giant disclosed plans to raise $1.75 billion through a private offering of convertible senior...

Simply Wall St 4d
Zoetis Valuation Check as Innovation Day, Dividend Hike and New Feline Drug Shape Growth Outlook

Zoetis (ZTS) just packed a lot into a short stretch, from showcasing a fuller innovation pipeline to lifting its dividend and winning Canadian approval for a ne...

Zoetis Valuation Check as Innovation Day, Dividend Hike and New Feline Drug Shape Growth Outlook
TipRanks 7d
Zoetis Announces 6% Increase in Quarterly Dividend

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

Simply Wall St 7d
Should Health Canada’s Portela Approval Shape How Zoetis Investors View Its OA Innovation Strategy?

Zoetis Inc. recently announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to provide three months of osteoa...

Should Health Canada’s Portela Approval Shape How Zoetis Investors View Its OA Innovation Strategy?

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.